Apotex scores exclusive Canadian rights to testosterone therapy Nebido

Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada

Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening

Hologic has been at the forefront of cervical cancer screening for decades

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls

Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children

Zydus receives FDA’s tentative approval for Dapagliflozin Tablets

Lupin launches Topiramate ER capsules in US

Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals

Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility

Inspection included drug device combinations covering our recent filing in nasal sprays domain

Novo Nordisk weathers pricing pressure, bets big on oral Wegovy

Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook

US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices

AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer

The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)